Loading...

BHVN BIOHAVEN LTD US FDA Inspections 8-K Filing

BHVN

BHVN

BIOHAVEN LTD

(BHVN)

2025 8-K

Show Summary

Show Summary

Investor Meetings

Pre-Market Approval

Financial Statements

Equity Offerings

Financial Results

Investor Presentation

Q3 Financial Results

Positive Study Results

Share Resale Filing

Equity Offering

Financial Results Announcement

Financial Results Announcement

Annual Meeting Results

Presentation Update

Prospectus Supplement Filing

Financial Results Announcement

Investor Presentation

Equity Distribution Agreement

Earnings Reports

Regulation FD Disclosure

Earnings Reports

Amendment and Annual Meeting

Publication of Investor Pre...

Financial Results Announcement

Analyst and Investor Meetings

External Links:

On May 14, 2025, Biohaven Ltd. announced that the FDA has extended the review period for its drug application for troriluzole by three months, now expecting a decision in Q4 2025.

AI Assistant

BIOHAVEN LTD

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.